SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

Australia were there for the taking but Brendon McCullum’s tourists were so poor and ill prepared they never got close ...

2025 was supposed to be the year of the AI agent. Companies invested heavily in autonomous systems that could handle tasks ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Semiconductors and data centers are emerging as the critical leverage points of the physical backbone of the AI economy.

As the war grinds on, sophisticated Russian defenses have pushed Ukraine to develop a frightening new weapon: semiautonomous killing machines.

Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more about RZLT stock here.

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.

Key 2026 milestones for SeaStar Medical include the following: Broaden QUELIMMUNE adoption to include 15 additional top-ranked children’s medical centers, more than doubling the total number of sites ...

And while most eyes were on the US in 2025, one consequence of the Trump administration’s new national security strategy ...